Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis-Reference-Cited by-同舟云学术

Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis

Published:2023-03-23 Issue:3-4 Volume:28 Page:288-298
ISSN:1083-7450
Container-title:Pharmaceutical Development and Technology
language:en
Short-container-title:Pharmaceutical Development and Technology

Author:

Gao Yu¹^ORCID,Shelling Andrew N.²^ORCID,Porter David³^ORCID,Leung Euphemia⁴^ORCID,Wu Zimei¹^ORCID

Affiliation:

1. School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand

2. Department of Obstetrics and Gynaecology, School of Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand

3. Auckland Regional Cancer and Blood Service, Auckland City Hospital, Auckland, New Zealand

4. Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/10837450.2023.2191277

Reference46 articles.

1. The critical role of mobile phase composition in size exclusion chromatography of protein pharmaceuticals

2. Physical Instabilities of Therapeutic Monoclonal Antibodies: A Critical Review

3. Physicochemical Stability of Monoclonal Antibodies: A Review

4. The effects of shear flow on protein structure and function

5. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stability indicating RP-HPLC method for the simultaneous estimation of Trastuzumab and Pembrolizumab in pharmaceutical dosage forms;Research Journal of Pharmacy and Technology;2024-05-15

2. Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells;Journal of Liposome Research;2024-01-25

3. Focused physicochemical stability study of reconstituted trastuzumab biosimilar SB3 (Ontruzant^®) stored in the original vials over 28 days;Pharmaceutical Technology in Hospital Pharmacy;2024-01-01